Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease. · Phase II
704 (USA) · Dr. Tanaka
consented 2012-12-07
AEs
1
Serious
0
Dropout signal
–
Adverse events
moderate
assessed
Moderate HEADACHE — outcome: NOT RECOVERED/NOT RESOLVED; onset 2012-08-23 (study day -106.0); relationship: NONE
Data queries
No data queries.